

### **Current Reporting of Material Corporate Events**

As of June 24, 2021, the number of shares outstanding of our Common Stock was 534,591,194.

#### **Disclosure Statement Pursuant to the OTC Pink Basic Disclosure Guideline**

Corporate Events:

#### **Entry into or termination of a material definitive agreement, and Sales of equity securities.**

Curative Biotechnology, Inc. (the “Company”) is announcing that on May 21 2021, the Company entered into a subscription agreement (the “Agreement”) with an accredited investor (the “Investor”) to sell 10,000,000 units (“Units”), with each Unit consisting of (i) 1 share of common stock of the Company (“Common Stock”) and (ii) one half (1/2) of a warrant to purchase one share of Common Stock (each, a “Warrant”). The price per Unit sold was \$0.06 for aggregate gross proceeds of \$600,000 to the Company. Accordingly, the Company issued the Investor (i) 10,000,000 shares of Common Stock (the “Shares”) and (ii) 5,000,000 Warrants to purchase one (1) share of Common Stock per Warrant. The Shares and Warrants are immediately separable on issuance.

The Warrants have (i) an exercise price of \$0.11 per share, (ii) a term of five (5) years from the date of issuance, and (iii) are subject to adjustment upon stock dividends and splits as more fully set forth in the Warrants.

The securities offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This current report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

#### **Disclosure Certification**

Principal Executive Officer

I, I Richard Garr, certify that I have reviewed this Material Corporate Event of Curative Biotechnology, Inc.

6/24/2021

/s/ I Richard Garr